SCHAUMBURG, Ill., March 19 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company today announced that it has launched ciprofloxacin injection, USP, 5% dextrose premix bag, a synthetic broad spectrum antimicrobial agent for intravenous (I.V.) administration used to treat bacterial infections. Sagent's ciprofloxacin injection will be available immediately in 200mg and 400mg premix bags. According to IMS data, sales of injectable ciprofloxacin in the United States in 2006 were approximately $60 million.
"We are poised to be one of the first companies to make the I.V. form of this important antibiotic widely available to patients in the U.S.," said Jeffrey M. Yordon, chief executive officer, founder, and chairman of the board of Sagent. "The launch of our ciprofloxacin -- in ready-to-use, customer friendly, barcoded I.V. bags -- simultaneous with the expiry of the innovator's patent exclusivity further demonstrates Sagent's capabilities and expertise in injectable pharmaceutical products and our seasoned management team's commitment to the needs of patients and customers."
Ciprofloxacin is the third product introduced from Sagent's pipeline of more than 200 products since the launch of the company's first product, adenosine injection, USP, in December 2007. Earlier this month, the company launched another antibiotic, cefazolin for injection, USP, which is available in 1g single dose vials and 10g pharmacy bulk package vials.
Ciprofloxacin injection, USP, is a synthetic broad spectrum
antimicrobial agent for intravenous administration used to treat a variety
of infections and is the generic equivalent of Bayer Pharmaceuticals'
CIPRO(R) I.V. Ciprofloxacin belongs to the fluoroquinolone family of drugs.
Ciprofloxacin injection, USP, is indicated for infections of the urinary
tract, skin and skin structure, bones and joints, as well as nosocomial
pneumonia, acute sinusitis, chro
|SOURCE Sagent Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved